- The first explores trial site and structural factors, looking at logistics, staffing, and data-sharing tools that impact accessibility.
- The second focuses on trial design and operational factors, including aspects such as trial location, duration, and participant experience.
- The third section delves into patient-level and disease factors, examining how age, treatment options, and disease severity influence participation.
All responses are strictly anonymous, and only aggregated data will be shared—individual answers will never be disclosed. Insights from multiple stakeholders will help us understand the structural, operational, and patient-level factors that impact enrolment and create solutions that make trials more inclusive, patient-centric and effective. By participating, respondents can play a vital part in advancing enrolment strategies for rare and ultra-rare disease trials worldwide.
This consultation process will close on 28 January 2026.